Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects
Conditions
Interventions
ALN-TTRSC02
Sterile Normal Saline (0.9% NaCl)
Locations
1
United Kingdom
Clinical Trial Site
London, United Kingdom
Start Date
June 7, 2016
Primary Completion Date
January 12, 2018
Completion Date
January 12, 2018
Last Updated
September 21, 2018
Lead Sponsor
Alnylam Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions